Contineum Therapeutics, Inc. Class A Common Stock (CTNM) Stock
Key stats
- Market cap
- $422.89M
- Price / Earnings ratio
- -6.5x
- EPS (TTM)
- -$1.77
- Volume
- Loading
- 52-week high
- $17.79
- 52-week low
- $6.73
Source: third-party data provider, as of November 13, 2026
Compare with CTNM
Recent news

Contineum Therapeutics Reports Third-Quarter 2026 Financial Results
Contineum Therapeutics Reports Third-Quarter 2026 Financial Results
CTNM

Contineum Therapeutics to Present at the Stifel 2026 Healthcare Conference
Contineum Therapeutics to Present at the Stifel 2026 Healthcare Conference
CTNM

All You Need to Know About Contineum Therapeutics, Inc. (CTNM) Rating Upgrade to Buy
All You Need to Know About Contineum Therapeutics, Inc. (CTNM) Rating Upgrade to Buy
CTNM

CTNM Stock Slumps 10% After-Hours — What’s The JNJ Connection?
CTNM Stock Slumps 10% After-Hours — What’s The JNJ Connection?
CTNM
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 55.83
- MACD 12/26/9
- -0.26
- EMA 9 of MACD
- -0.66
- MACD histogram
- 0.39
- SMA 50
- $11.58
- Price below SMA 50
- EMA 50
- $11.10
- Price below EMA 50
- SMA 200
- $13.45
- Price below SMA 200
- EMA 200
- $12.57
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Hold
Based on 3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Contineum Therapeutics Reports Third-Quarter 2026 Financial Results
Contineum Therapeutics Reports Third-Quarter 2026 Financial Results
CTNM

Contineum Therapeutics to Present at the Stifel 2026 Healthcare Conference
Contineum Therapeutics to Present at the Stifel 2026 Healthcare Conference
CTNM

All You Need to Know About Contineum Therapeutics, Inc. (CTNM) Rating Upgrade to Buy
All You Need to Know About Contineum Therapeutics, Inc. (CTNM) Rating Upgrade to Buy
CTNM

CTNM Stock Slumps 10% After-Hours — What’s The JNJ Connection?
CTNM Stock Slumps 10% After-Hours — What’s The JNJ Connection?
CTNM

Contineum, J&J's depression drug fails to meet mid-stage trial goal
Contineum, J&J's depression drug fails to meet mid-stage trial goal
CTNM

Contineum Therapeutics Reports Phase 2 Results for JNJ-5120/PIPE-307 for the Treatment of Major Depressive Disorder
Contineum Therapeutics Reports Phase 2 Results for JNJ-5120/PIPE-307 for the Treatment of Major Depressive Disorder
CTNM

Contineum Therapeutics to Present at the 2026 Morgan Stanley Global Healthcare Conference
Contineum Therapeutics to Present at the 2026 Morgan Stanley Global Healthcare Conference
CTNM

Contineum Therapeutics Reports Second-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones
Contineum Therapeutics Reports Second-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones
CTNM

Are You Looking for a Top Momentum Pick? Why Contineum Therapeutics, Inc. (CTNM) is a Great Choice
Are You Looking for a Top Momentum Pick? Why Contineum Therapeutics, Inc. (CTNM) is a Great Choice
CTNM

Contineum Therapeutics Publishes Discovery of Potential Best-in-Class LPAR1 Antagonist PIPE-791 in Journal of Medicinal Chemistry
Contineum Therapeutics Publishes Discovery of Potential Best-in-Class LPAR1 Antagonist PIPE-791 in Journal of Medicinal Chemistry
CTNM
News tone: automated (AI) classification of the article's content, not a price prediction.
About Contineum Therapeutics, Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Carmine N. Stengone MBA, MS | President, CEO & Director | 1976 |
| Mr. Peter T. Slover CPA | Chief Financial Officer | 1975 |
| Dr. Timothy R. Watkins M.D., M.Sc. | Chief Medical Officer & Head of Development | 1974 |
| Ms. Morgan Paulsen | Senior Manager of Accounting | — |
| Dr. Daniel S. Lorrain Ph.D. | Chief Science Officer | 1969 |
| Mr. Steve E. Kunszabo | Senior Director of Investor Relations & Corporate Communications | — |
| Mr. John S. Healy | General Counsel & Corporate Secretary | 1972 |
| Mr. Austin Chen Ph.D. | Senior VP & Head of Research | — |
| Ms. Julie S. Iwashita | Senior Vice President of Clinical Operations | — |
| Ms. Kristina Haeckl Rac | Senior Vice President of Regulatory Affairs | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 55.83
- MACD 12/26/9
- -0.26
- EMA 9 of MACD
- -0.66
- MACD histogram
- 0.39
- SMA 50
- $11.58
- Price below SMA 50
- EMA 50
- $11.10
- Price below EMA 50
- SMA 200
- $13.45
- Price below SMA 200
- EMA 200
- $12.57
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $14.00
- Average
- $20.33
- High
- $30.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +0.0 | +1.6 | +1.9 | -18.9 | -27.7 | +12.7 |



